Evolus Inc. named Michael Jafar chief marketing officer, a new position, and its second recent hire from the executive ranks of Allergan plc.
Jafar comes was most recently vice president of body contouring, Coolsculpting, part of the medical aesthetics unit at Allergan. He joined Evolus about a month after Chief Executive David Moatazedi, who had been senior vice president of U.S. medical aesthetics there.
Moatazedi succeeded OC medical executive Murthy Simhambhatla as Evolus CEO.
Irvine-based Evolus is an aesthetics medicine company. Its first product, DWP-450, which was submitted to the Food and Drug Administration for approval to treat moderate to severe frown lines, is designed to produce similar cosmetic effects to Botox. Shares of the company recently traded at about $33 each for a $774 million market cap.
